Home Based Primary Care Physician

Clover Health adds Torricelli, Miller to board. Former U.S. Sen. Robert Torricelli, D-N.J., and Brian Miller, MD, have been appointed to Clover Health's board of directors, confirming the Clover Health Torricelli Miller board additions announced Sept. 24. What these Clover Health Torricelli Miller board roles will involve. Torricelli will serve on Clover's audit committee, while Miller will be on the clinical committee. This division of committee assignments reflects each new director's distinct background, financial and policy expertise for Torricelli, clinical and Medicare payment policy expertise for Miller. Torricelli's background before this Clover Health board appointment. Torricelli has been a director of Clover's insurance subsidiaries since 2022. He founded business strategy firm Rosemont Associates in 2002 and real estate development firm Woodrose Properties in 2003. He was also executive vice president and COO of healthcare services company Aveta, giving him direct prior healthcare industry operational experience beyond his political and business background. Miller's background behind this Clover Health Torricelli Miller board appointment. Miller is an associate professor at Baltimore-based Johns Hopkins University and has practiced at Johns Hopkins Hospital. Since May 2023, he has been a commissioner on the Medicare Payment Advisory Commission, an agency that advises Congress on Medicare. He has also been on the board of trustees for the North Carolina State Health Plan since January 2025 and became vice chairman in April 2026. Why Miller's federal policy background stands out. Previously, Miller held roles at CMS, the FDA, and federal commissions, giving him direct experience across multiple federal health regulatory and payment bodies. This combination of active MedPAC commissioner status alongside prior CMS and FDA experience positions Miller to bring current, firsthand insight into Medicare payment policy debates directly into Clover's boardroom. Leadership's statement on this Clover Health Torricelli Miller board appointment. "Bob brings deep ties to New Jersey communities, experience navigating federal policy and firsthand knowledge of Clover," Clover CEO Andrew Toy said in the news release. "Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently and generates meaningful savings." Why this combination of directors fits Clover's strategic needs. Toy's framing suggests the two appointments were chosen to complement each other: Torricelli's regional and organizational familiarity with Clover paired with Miller's national Medicare payment and technology policy perspective, potentially strengthening the board's ability to navigate both local market dynamics and evolving federal reimbursement policy simultaneously. How this fits Clover's broader board composition. Clover's board now has nine directors, with the appointments filling two vacancies. This board expansion follows Chelsea Clinton's earlier departure from Clover Health's board, meaning these two new directors are specifically replacing the resulting openings rather than representing a net increase in board size beyond its prior full complement. Why filling these vacancies with this specific expertise matters. Choosing a former senator with existing Clover subsidiary board experience and an active MedPAC commissioner with federal regulatory experience to fill these two vacancies suggests Clover prioritized candidates who could immediately contribute both organizational continuity and current Medicare policy expertise, rather than seeking entirely new outside perspectives. What this Clover Health Torricelli Miller board appointment means going forward. With Miller's active role on MedPAC, the federal commission that advises Congress on Medicare payment policy, Clover Health gains a board member with direct, current insight into the federal policy discussions shaping Medicare Advantage reimbursement, potentially valuable given Clover's business as a Medicare Advantage-focused insurer. Given Torricelli's existing tenure on Clover's insurance subsidiary boards since 2022, his elevation to the parent company board level reflects continuity in governance rather than the introduction of an entirely unfamiliar director. What to watch going forward. As Torricelli and Miller settle into their respective audit and clinical committee roles, industry observers will likely watch whether Miller's MedPAC perspective visibly shapes Clover's approach to Medicare Advantage payment strategy and quality initiatives. Given the broader context of significant executive and board transitions across the payer industry this year, this Clover Health Torricelli Miller board appointment adds to a pattern of insurers seeking directors with direct federal health policy experience as Medicare Advantage reimbursement and regulatory scrutiny continue intensifying industrywide.

Clover Health has appointed former US Senator Robert Torricelli and Dr Brian J. Miller to its board of directors, filling two vacant positions and bringing the board to nine directors. Senator Torricelli will serve on the audit committee, whilst Dr Miller will join the clinical committee. Torricelli represented New Jersey in Congress for 20 years and has served on Clover's insurance subsidiary board since 2022. Dr Miller is a practising hospitalist at Johns Hopkins Hospital and currently serves as a commissioner on the Medicare Payment Advisory Commission. Chief executive Andrew Toy said the appointments strengthen the board with expertise spanning public service, Medicare Advantage, clinical practice and healthcare policy. The company operates a physician enablement technology platform and provides Medicare Advantage plans across several US states.

Clover Health welcomes former U.S. Senator Robert Torricelli and medpac Commissioner Dr. Brian J. Miller M.D. to its Board of Directors. WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) - Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., to the Company's Board of Directors, effective immediately. The appointments bring together two accomplished leaders whose complementary experience spans public service, Medicare Advantage, clinical practice, healthcare policy, and business. Senator Torricelli will serve on the Board's Audit Committee, and Dr. Miller will serve on its Clinical Committee. The appointments fill the Board's two previously disclosed vacancies and bring the Board to nine directors. "Today marks an exciting step forward for Clover, and we are thrilled to welcome Bob and Brian to our Board," said Andrew Toy, Chief Executive Officer of Clover Health. "Bob brings deep ties to New Jersey communities, experience navigating federal policy, and firsthand knowledge of Clover. Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently, and generates meaningful savings. Together, their experience, judgment, and perspectives will strengthen our Board and reinforce our ability to execute with discipline, grow responsibly, and build lasting value for our members, physicians, and shareholders." "From the beginning, we built Clover around the belief that some of the hardest problems in healthcare can be solved by challenging long-held assumptions about how healthcare works and care is delivered," added Vivek Garipalli, Co-founder of Clover Health and Executive Chairperson of the Board. "As Clover grows, it is important that our Board continues to reflect the complexity of the healthcare system we are working to improve and brings together special individuals who understand it from fundamentally different vantage points. Bob and Brian add tremendous depth across public policy, medicine, Medicare and business, and their perspectives will be invaluable as we drive forward on Clover's mission to Improve Every Life." Senator Torricelli brings a distinctive combination of deep New Jersey roots, national policymaking experience, and firsthand knowledge of Clover. For 20 years, he represented New Jersey in the U.S. House of Representatives and the U.S. Senate, where his committee service included the Senate Finance Committee and work on federal financing for healthcare institutions. Following his congressional career, he founded Rosemont Associates, a business strategy firm, and established Woodrose Properties, a real estate development business. Since 2022, he has served on the board of the Company's insurance subsidiaries, giving him firsthand familiarity with Clover's business, mission, and approach to Medicare Advantage. Additionally, Senator Torricelli has served as a director of Glassbridge Enterprises, Inc. since February 2017 and previously served as executive vice president and chief operating officer of Aveta, Inc., a healthcare services company. His experience navigating complex policy and business issues will bring a valuable perspective to Clover's Board and Audit Committee. "Through my years living in New Jersey and representing its communities in Congress, I have come to know the challenges many seniors face in accessing high-quality, affordable care," said Senator Torricelli. "Through my service on Clover's insurance subsidiary board, I have seen the Company's commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach. I am honored to join the Board and excited to contribute to its oversight, support this talented team, and help Clover build lasting value for members and shareholders." Dr. Miller brings a rare combination of frontline clinical practice and national Medicare policy leadership. A practicing hospitalist at the Johns Hopkins Hospital, an Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Visiting Fellow at the Hoover Institution, Dr. Miller brings to Clover broad ranging regulatory experience spanning the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, and the Federal Trade Commission. He currently serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan and as a Commissioner on the Medicare Payment Advisory Commission (MedPAC), the independent, nonpartisan commission that advises Congress on Medicare payment policy. Board-certified in internal medicine and preventive medicine, Dr. Miller offers a practical perspective on improving care delivery and advancing a more effective Medicare program. "As a practicing physician, I see every day how much better technology can support clinical practice when it delivers the right information at the point of care," said Dr. Miller. "Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden for physicians or patients. Clover is building a differentiated model for Medicare Advantage: flexible and nimble, powered by technology, and close enough to physicians and patients to translate innovation into action. I am delighted to join the Board and look forward to helping Clover advance this approach and deliver a better care experience for people on Medicare." About Clover Health Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.